Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6988843 | 0.88 | SHBG (0.39) | SHBGEPHX1CYP1A2 | |
| SCHEMBL7458138 | 0.86 | SHBG (0.38) | SHBGEPHX1CYP1A2 | |
| SCHEMBL7457530 | 0.85 | TSHR (0.38) | EPHX1 | |
| SCHEMBL7457424 | 0.85 | TSHR (0.38) | EPHX1 | |
| SCHEMBL7452808 | 0.85 | TSHR (0.38) | EPHX1 | |
| SCHEMBL7458659 | 0.85 | TSHR (0.38) | EPHX1 | |
| SCHEMBL7453115 | 0.85 | TSHR (0.38) | EPHX1 | |
| SCHEMBL7463334 | 0.85 | TSHR (0.38) | EPHX1 | |
| SCHEMBL12987447 | 0.83 | SHBG (0.50) | SHBGSMN1; SMN2EPHX1KDM4EALDH1A1 | |
| SCHEMBL741065 | 0.83 | SHBG (0.50) | SHBGSMN1; SMN2EPHX1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869930-B1 | Acylated insulin | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| US-6011007-A | ZN2+ COMPLEX. | NOVO NORDISK A/S (DK) | 2000-01-04 | — | — | US | claimed |
| US-10195254-B2 | Myristoylated leptin-related peptides and uses thereof | ALBANY MEDICAL COLLEGE (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170312340-A1 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | ALBANY MEDICAL COLLEGE (US) | 2017-11-02 | — | — | US | disclosed |
| EP-3180021-A2 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | Albany Medical College (US) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016025459-A2 | MYRISTOYLATED LEPTIN-RELATED PEPTIDES AND USES THEREOF | ALBANY MEDICAL COLLEGE (US) | 2016-02-18 | — | — | WO | disclosed |
| US-8486947-B2 | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2013-07-16 | — | — | US | disclosed |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | disclosed |
| US-7910605-B2 | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2011-03-22 | — | — | US | disclosed |
| EP-1745002-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-08-19 | — | — | US | disclosed |
| EP-0982300-A2 | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2000-03-01 | — | — | EP | disclosed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | disclosed |
| US-5639775-A | COGNITION ACTIVATORS | THE UNIVERSITY OF TOLEDO (US) | 1997-06-17 | — | — | US | disclosed |
| US-5633382-A | Histamine H3 -receptor antagonists and therapeutic uses thereof | THE UNIVERSITY OF TOLEDO (US) | 1997-05-27 | — | — | US | disclosed |
| US-5486526-A | APPETITE SUPPRESSANTS | THE UNIVERSITY OF TOLEDO (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995011894-A1 | HISTAMINE H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF | THE UNIVERSITY OF TOLEDO (US) | 1995-05-04 | — | — | WO | disclosed |
| EP-0633882-A1 | 4- 4'-PIPERIDINYL OR 3'-PIRROLIDINYL] SUBSTITUTED IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF | THE UNIVERSITY OF TOLEDO (US) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993020061-A1 | 4-[4'-PIPERIDINYL OR 3'-PIRROLIDINYL] SUBSTITUTED IMIDAZOLES AS H3-RECEPTOR ANTAGONISTS AND THERAPEUTIC USES THEREOF | THE UNIVERSITY OF TOLEDO (US) | 1993-10-14 | — | — | WO | disclosed |
| EP-0187589-B1 | PROCESS FOR RECOVERING MOLYBDENUM-99 FROM A TARGET OF AN IRRADIATED URANIUM ALLOY | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210653-A1 | Novel Compounds, Their Preparations and Use | PPARG, PPARD, PPARA | SHBG 718/4885SMN1; SMN2 2610/4885EPHX1 1901/4885 |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | SHBG 4455/4885SMN1; SMN2 3925/4885EPHX1 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.